Comorbid LUTS and erectile dysfunction: optimizing their management

References

• Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005;47:511–17
   PubMed Web of Science ®Google Scholar
• Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47:824–37
   Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61
   PubMed Web of Science ®Google Scholar
• Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int 2002;89:208–13
   Google Scholar
• Vallancien G, Emberton M, Harving N, et al.; for the Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003;169: 2257–61
   Google Scholar
• Braun MH, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical ‘aging male’ symptoms? Results of the ‘Cologne Male Survey.’ Eur Urol 2003;44:588–94
   PubMed Web of Science ®Google Scholar
• Nicolosi A, Glasser DB, Moreira ED, et al.; Erectile Dysfunction Epidemiology Cross National Study Group. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003;15:253–7
   Google Scholar
• Ponholzer A, Temml C, Obermayr R, et al. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004;64:772–6
   PubMed Web of Science ®Google Scholar
• Shiri R, Häkkinen JT, Hakama M, et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 2005;174:205–9
   PubMed Web of Science ®Google Scholar
• Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey.’ Int J Impot Res 2000;12:305–11
   PubMed Web of Science ®Google Scholar
• Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urology 2000;163:460–3
   PubMed Web of Science ®Google Scholar
• Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281: 537–44
   Google Scholar
• Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ 2001;323:1042–6
   PubMed Web of Science ®Google Scholar
• Narayan P, Indudhara R. Pharmacotherapy for benign prostatic hyperplasia. West J Med 1994;161:495–506
   PubMedGoogle Scholar
• Cassel CK, ed. Geriatric Medicine: An Evidence-based Approach, 4th edn. New York: Springer-Verlag, 2003
   Google Scholar
• Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–9
   PubMed Web of Science ®Google Scholar
• Garraway W, Russell EBAW, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Practice 1993;43: 318–21
   PubMed Web of Science ®Google Scholar
• Schiff JD, Mulhall JP. The link between LUTS and ED: clinical and basic science evidence. J Androl 2004;25:470–8
   PubMed Web of Science ®Google Scholar
• Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998;51:428–36
   PubMed Web of Science ®Google Scholar
• Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840–4
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151–8
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157–62
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano F, Martedì E, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005;28:1201–3
   Google Scholar
• Azadzoi KM, Master TA, Siroky MB. Effect of chronic ischemia on constitutive and inducible nitric oxide synthase expression in erectile tissue. J Androl 2004;25:382–8
   Google Scholar
• Lepor H, Tang R, Kobayashi S, et al. Localization of the alpha 1A-adrenoceptor in the human prostate. J Urol 1995;154: 2096–9
   PubMed Web of Science ®Google Scholar
• Levin RM, Wein AJ. Adrenergic alpha receptors outnumber beta receptors in human penile corpus cavernosum. Invest Urol 1980;18:225–6
   PubMedGoogle Scholar
• Buzelin JM, Fonteyne E, Kontturi M, et al; The European Tamsulosin Study Group. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:597–605
   Google Scholar
• Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res 2000;12(Suppl 1):S48–63
   Web of Science ®Google Scholar
• McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5: 251–7
   PubMedGoogle Scholar
• Fawcett L, Baxendale R, Stacey P, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A 2000;97:3702–7
   PubMed Web of Science ®Google Scholar
• McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838–45
   PubMed Web of Science ®Google Scholar
• Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006;3:676–81
   PubMed Web of Science ®Google Scholar
• AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170: 530–47
   Google Scholar
• Stage AC, Hairston JC. Symptom scores: mumbo jumbo or meaningful measures? Curr Urol Rep 2005;6:251–6
   PubMedGoogle Scholar
• O’leary MP. Treatment and pharmacologic management of BPH in the context of common comorbidities. Am J Manag Care 2006;12(5 Suppl):S129–40
   PubMed Web of Science ®Google Scholar
• Rosen RC, Capelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319–26
   PubMed Web of Science ®Google Scholar
• Cappelleri JC, Siegel RL, Glasser DB, et al. Relationship between patient self-assessment and erectile dysfunction and the sexual health inventory for men. Clin Ther 2001;23: 1701–19
   Web of Science ®Google Scholar
• Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006;28:13–25
   Google Scholar
• Ansong KS, Lewis C, Jenkins P, Bell J. Help-seeking decisions among men with impotence. Urology 1998;52:834–7
   PubMed Web of Science ®Google Scholar
• Schou J, Holm NR, Meyhoff HH. Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1996;179:119–22
   PubMedGoogle Scholar
• Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398–405
   Google Scholar
• Furuya S, Kumamoto Y, Yokoyama E, et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982;128:836–9
   PubMed Web of Science ®Google Scholar
• Flomax [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2005
   Google Scholar
• Hatano A, Takahashi H, Tamaki M, et al. Pharmacological evidence of distinct α1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994;113:723–8
   PubMed Web of Science ®Google Scholar
• Price D. Potential mechanisms of action of superselective alpha1-adrenoceptor antagonists. Eur Urol 2001;40(Suppl 4):5–11
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 2006;67:225–31
   PubMed Web of Science ®Google Scholar
• Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994;44:46–51
   PubMed Web of Science ®Google Scholar
• Höfner K, Claes H, De Reijke TM, et al; for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36: 335–41
   Google Scholar
• Food and Drug Administration. ALFOTAM trial. Center for Drug Administration and Research. Available at: www. pbm.va.gov/criteria/Alpha-Blocker%20CFU%207–2005.pdf [Accessed 11 May 2006]
   Google Scholar
• Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257–61
   PubMed Web of Science ®Google Scholar
• Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med 2006;166:565–71
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Hoesl CE, et al. Alpha-adrenoreceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS – implications for clinical practice. Andrologia 2006;38:1–12
   PubMed Web of Science ®Google Scholar
• Cialis [package insert]. Indianapolis, IN: Lilly ICOS LLC, 2005
   Google Scholar
• Levitra [package insert]. West Haven, CT: Bayer Pharmaceutical Corporation, 2005
   Google Scholar
• Viagra [package insert]. New York, NY: Pfizer, Inc, 2005
   Google Scholar
• Auerbach SM, Gittelman M, Mazzu A, et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64:998–1003
   PubMed Web of Science ®Google Scholar
• Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006;67:1199–204
   PubMed Web of Science ®Google Scholar
• Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172:1935–40
   PubMed Web of Science ®Google Scholar
• Narayan P, Gagnier P, Doyle C. Concomitant use of sildenafil with tamsulosin or terazosin – a retrospective safety evaluation. J Urol 2004;171(Suppl):357. Abstract 1356
   Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al; for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98
   Google Scholar
• Kirby RS, Roehrborn C, Boyle P, et al; PREDICT Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61: 119–26
   Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, et al; for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyper-plasia. N Engl J Med 1998;338:557–63
   Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, et al; ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60: 434–41
   Google Scholar
• Barkin J, Guimarães M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003;44:461–6
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Giannakopoulos X, Maehlum O, et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyper-plasia: clinical outcome up to five years from three centers. Eur Urol 2003;44:89–93
   PubMed Web of Science ®Google Scholar
• Rosario DJ, Woo H, Potts KL, et al. Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997;80:579–86
   PubMedGoogle Scholar
• Bruskewitz R, Issa MM, Roehrborn CG, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159:1588–94
   PubMed Web of Science ®Google Scholar
• Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol 2003;17: 103–7
   Google Scholar
• Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow-up. J Urol 1997;158:1834–8
   PubMed Web of Science ®Google Scholar
• Hoffman RM, MacDonald R, Wilt TJ. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev 2004;(1). Art. No.: CD001987. DOI: 10.1002/14651858. CD001987.pub2.
   Google Scholar
• Cerruti G, Tani F. TUIP for infravesically obstructed BPH patients: a review of 300 cases. Arch Esp Urol 1994;47:911–14
   PubMedGoogle Scholar
• Riehmann M, Knes JM, Heisey D, et al. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995;45:768–75
   PubMed Web of Science ®Google Scholar
• Te AE, Malloy TR, Stein BS, et al. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int 2006;97:1229–33
   PubMed Web of Science ®Google Scholar
• Bachmann A, Schurch L, Ruszat R, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol 2005;48:965–71
   PubMed Web of Science ®Google Scholar
• Hammadeh MY, Madaan S, Hines J, et al. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 2003;61:1166–71
   PubMed Web of Science ®Google Scholar
• Wasson JH, Reda DJ, Bruskewitz RC, et al; The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995;332:75–9
   Google Scholar